normal  medium  large

  • Professor, Department of Medicine
  • Director, Hematopoietic Stem Cell Transplantation Program
  • Director, Hematologic Malignancy Program

Board Certification

  • Internal Medicine - Hematology
  • Internal Medicine


Medical School
  • MD, Dartmouth Medical School, NH (1980)
Residency Training
  • Internal Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, MA (1983)
Fellowship Training
  • Hematology/Oncology, Beth Israel Deaconess Medical Center/Harvard Medical School, MA (1987)


  • Internal Medicine


  • Hematology and Oncology

Clinical Interests/Expertise

  • Hematologic Malignancies
  • Hematopoietic Stem Cell Transplantation

Research Interests/Expertise

  • Cytokines
  • Transplantation immunology
  • New drug development in hematological malignancies and cancer
  • Detection of minimal residual disease in lymphoma
  • MDR expression in leukemic cells
  • Cachexia
Lea Baer

Contact Information

Internal Medicine
3 Edmund D Pellegrino Rd.,
Stony Brook, NY 11794-9447.

Telephone Ph.: 631-638-1000

  • Personal Statement
  • Honors
  • Publications
  • Grants/Trials

  • New York Magazine's Best Doctors, 2 consecutive years, 2013-2014
  • One of the "Doctors of Excellence" featured in the previous and the latest editions (2013) of the Castle Connolly Guides, Top Doctors: New York Metro Area, America's Top Doctors for Cancer, and America's Top Doctors
  • New York Magazine's Best Doctors in New York, 9 consecutive years, 2002 - 2010
  • Member of American Medical Association
  • Member of American College of Physicians
  • Member of American Society of Clinical Oncology
  • Member of American Society of Hematology
  • Member of New York Blood Club
  • Member of American Society of Bone Marrow and Stem Cell Transplantation
  • Member of International Society for Hematotherapy and Graft Engineering
  • Member of The Bone Marrow Foundation (Board of Advisors Member)

  • For articles published by Dr. Schuster, click here.

  • NOVARTIS PHARMACEUTICALS CORPORATION: A Single-Arm, Open-Label, Multi-Center Study of Complete Molecular Response (CMR) in Adult Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
  • CASE WESTERN RESERVE UNIVERSITY:  A Multicenter, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB)
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - CELATOR PHARMACEUTICALS INCORPORATED - Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adult Patients 1 Month Duratio
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - U S BIOTEST INCORPORATED - Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma or Non-Hodgkin Lymphoma Undergoing
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - AEGERA THERAPEUTICS INCORPORATED - A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - MERCK AND COMPANY - A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - SUNESIS PHARMACEUTICALS INCORPORATED - A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed of Refractory Acute Myeloid Leukemia (VALOR)
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - ICON CLINICAL RESEARCH - BMS: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5 Year Prospective Cohort Study (SIMPLICITY)
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - AMGEN INCORPORATED - A Phase I Study Evaluating the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related Disorders
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - KIADIS PHARMA NETHERLANDS B V - An Open-Label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR), Through the Use of TH9402 and Light Treatment in an Ex Vivo Process
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - SCHERING PLOUGH RESEARCH INSTITUTE - Pharmacokinetics, Safety and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1B)
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - THERAKOS INCORPORATED - An International Randomized Controlled Study of Extracorporeal Photopheresis Therapy for the Treatment of Patients with Chronic Graft-versus-Host Disease
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - CYCLACEL LIMITED - A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - MERCK SHARP AND DOHME CORPORATION - A Phase III, Randomized, Placebo-Controlled, Clinical Trial t Study the Safety and Efficacy, of V212 in Adult Patients with Solid Tumor or Hematopoietic Malignancy
  • CLINICAL TRIAL: PRINCIPAL INVESTIGATOR - COVANCE - TaiGen: Phase II, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease